RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Add to Collection
2014 May RCTs Fist_Author_Year_PM

Full Author : ['Barnett, Anthony H', 'Mithal, Ambrish', 'Manassie, Jenny', 'Jones, Russell', 'Rattunde, Henning', 'Woerle, Hans J', 'Broedl, Uli C']
Journal Title : The lancet. Diabetes & endocrinology
Chapter : Section3
Journal Year : 2014
Cited by : Not Available

BACKGROUND: Diabetes is a leading cause of chronic kidney disease (CKD) worldwide. Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk of microvascular and macrovascular complications and to slow the progression of.....

Keywords : ["randomised doubleblind placebocontrolle trial", "exist antidiabete treatment", "chronic kidney disease", "type diabetes", "empagliflozin add", "safety", "patient", "efficacy"]